Overview
- The peer-reviewed PLOS Medicine study by Cleary and colleagues analyzed national registry data on more than 1.2 million births for autism and over 900,000 for ADHD in Sweden.
- Unadjusted data showed higher diagnosis rates with exposure (autism 2.0% unexposed vs 2.9% low dose and about 3.6–3.9% high dose), with a similar pattern for ADHD.
- After controlling for genetic, familial, and environmental confounders through multiple designs, including sibling comparisons and pre-pregnancy prescription controls, the apparent risks disappeared.
- Very high doses or prolonged use were uncommon in the dataset, leaving uncertainty at those extremes, and the research remains observational.
- Authors advise weighing pain treatment needs in pregnancy and offering psychosocial and evidence-based options, noting the work was supported by the U.S. National Institute on Drug Abuse.